Abstract
Bayer Pharma and Evotec have entered into a 5-year partnership aimed at developing three clinical candidates for the treatment of endometriosis. Both companies will contribute drug targets and will be jointly responsible for early research and preclinical characterisation. Bayer will then undertake any subsequent clinical development and commercialisation. Bayer already markets the progesterone receptor agonist Visanne® (dienogest) for the treatment of endometriosis and the deal could help strengthen the company’s women’s healthcare business in the long term.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
